Mode
Text Size
Log in / Sign up
N/A N=8

Continuous Cardiac Arrhythmia Monitoring in Hemodialysis Patients

Arrhythmias, Cardiac

Enrolled (actual)
8
Serious AEs
0.0%
Results posted
Mar 2013
Primary outcome: Primary: Number of Participants With a Significant Arrhythmia Detected — 0 participants

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
continuous cardiac monitoring device (REVEAL, Medtronic) (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Duke University
Primary completion
Feb 2011

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants With a Significant Arrhythmia Detected
SECONDARY
Number of Participants Experiencing a Peridialytic or Intradialytic Arrhythmias

Summary

Hemodialysis patients have a rate of fatal arrhythmias that is 40 times greater than the general population, but the causes and types of fatal arrhythmias they experience is unclear. The purpose of this prospective observational cohort study is to capture and characterize occult arrhythmias which occur in hemodialysis patients over a 6 month period. After informed consent and baseline assessment, 30 adult hemodialysis patients without a prior history of cardiac arrhythmias will undergo implantation of a continuous cardiac monitoring device (REVEAL, Medtronic). Three followup visits will be scheduled to download device data and quantify the number of potentially malignant arrhythmias which occur in study subjects during the 6 month period. Additionally, captured events will be monitored remotely via regular patient initiated transmission of device data every 2 weeks. Any serious occult arrhythmias detected will be immediately acted upon with a predefined management algorithm. Descriptive data and simple proportions will be used to describe the incidence and types of arrhythmias among the study cohort. Risks of this study include 1) potential loss of patient confidentiality 2) risks related to insertion of device including pocket hematoma, device infection, pain and discomfort secondary to procedure. These will be minimized by strict security measures to protect each patient's protected health information (PHI), preprocedural screening and insertion of monitoring devices by highly trained operators, and frequent careful direct patient followup.

Eligibility Criteria

Inclusion Criteria

  • Greater than 18 years of age
  • ESRD receiving hemodialysis for at least 3 months

Exclusion Criteria

  • Inability to give informed consent
  • Pre-existing implantable cardiac device (pacemaker or ICD) or imminent device implantation
  • Imminent renal transplantation
  • Life expectancy 1.7 upper limit of normal (ULN) or history of bleeding diathesis
  • Unstable medical condition as deemed by primary nephrologist or study staff
  • Known sustained ventricular tachycardia due to non-reversible cause.
  • Active infection
  • Known atrial fibrillation
  • Women who are pregnant
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00932659). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search